Revvity, Inc. (RVTY) is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates across two segments: life sciences, which supplies reagents and instruments to biopharma and academic researchers, and diagnostics, which provides immunodiagnostics and newborn and reproductive health screening. With a market capitalization of roughly $14 billion and a presence across the United States, Europe, and China, Revvity is a meaningful player in the broader healthcare tools and diagnostics industry.
As the stock has climbed toward its 52-week high, investors have increasingly focused on whether it can push meaningfully higher. The $145 figure is not arbitrary — it matches the highest analyst price target among the firms covering the name, according to S&P Global data. With the stock recently trading near $126.59, reaching $145 would imply an advance of roughly 14%. That is a meaningful but not extreme move, making the level a realistic focal point for the current market outlook.
Revvity shares have delivered a strong run, gaining roughly 30% over the past year and sitting just below their 52-week high near $130. The stock's 52-week range spans from about $81 to $130, underscoring both the recovery that has already occurred and the resistance zone the shares are now testing. Trading near the upper boundary of this range means the stock must clear a well-defined supply area before a sustained push toward $145 becomes technically credible.
Several factors support the case for continued appreciation. First, the diagnostics business has shown durable performance, with management raising full-year guidance on the back of a solid second quarter. Second, life sciences demand is showing signs of improvement, supported by a growing backlog tied to AI-related research spending that analysts believe could convert into incremental revenue as preclinical R&D budgets recover. Third, a broad recovery in the life sciences tools sector — driven by healthier procedure volumes and capital expenditure trends — could provide a favorable tailwind across 2026.
The consensus analyst rating on Revvity is a "Buy," but the dispersion of price targets reveals genuine uncertainty. The average target sits near $121.94, with a low of $100 and a high of $145. Recent actions illustrate the mixed tone: RBC Capital initiated coverage with a Sector Perform rating and a $135 target, while TD Cowen maintained a Buy rating with a $130 target. Others, including JPMorgan, Wells Fargo, and Stifel, hold targets near $110. Notably, the $145 high target is an outlier well above the consensus, suggesting that reaching it would require conditions to evolve more favorably than most analysts currently expect.
Valuation is the central hurdle in the $145 debate. Revvity trades at a trailing price-to-earnings (P/E) ratio near 61, well above its five-year median of roughly 30. Even with projected earnings per share (EPS) growth — consensus estimates point to EPS rising from about $5.35 in 2026 to roughly $5.89 the following year — the stock's multiple already embeds meaningful optimism. For $145 to be reached without further multiple expansion, the market would need to see an acceleration in organic growth that is not yet fully reflected in current revenue forecasts, which call for essentially flat sales in 2026.
Several risks stand in the way. Projected 2026 revenue is roughly flat versus 2025, and analysts have flagged structural challenges to the company's long-term 6% to 8% organic growth target. Exposure to China adds both policy and demand uncertainty, and RBC's cautious initiation specifically cited a need for greater confidence in the growth outlook. Elevated valuation also leaves the stock vulnerable to multiple compression if execution disappoints or the broader tools sector recovery stalls. Any of these factors could keep the shares range-bound below $130 rather than propelling them toward $145.
Traders tracking names like Revvity may find value in automated tools that continuously scan the market for shifting conditions. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving technical behavior and AI-driven analysis. The platform is designed to help traders spot opportunities, keep tabs on existing positions, and identify changing market trends more efficiently than manual review alone. For those following whether a stock can sustain momentum toward a higher target, these signals offer a convenient way to stay informed on daily shifts.
Reaching $145 is a plausible but demanding scenario for Revvity. The company benefits from durable diagnostics demand, an improving life sciences backdrop, and a growing AI-related research pipeline, and the stock's strong momentum shows investors are rewarding that narrative. At the same time, flat projected 2026 revenue, an elevated P/E ratio, and China-related risks mean the $145 level — the top of the analyst range — is not a base case. Investors should monitor organic growth trends, guidance revisions, and whether the shares can first clear and hold above the $130 zone. The gap between the consensus target near $122 and the $145 high target neatly captures the range of realistic outcomes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +2.79% | ||
| TMO - RVTY | 70% Closely correlated | +1.10% | ||
| A - RVTY | 65% Loosely correlated | +2.66% | ||
| CRL - RVTY | 65% Loosely correlated | +1.93% | ||
| AZTA - RVTY | 63% Loosely correlated | +2.22% | ||
| IQV - RVTY | 63% Loosely correlated | +1.74% | ||
More | ||||